Colgate-Palmolive Company CL · NYSE
$91.61 -0.61% (-$0.56)
Summary
75 / 100 · Bulios Score
What speaks for it
- It earns 30 USD a year on every 100 USD of invested capital.
- It has raised its dividend 11 years in a row.
- Earnings per share grew by 7.3% a year over the last 3 years.
- Out of every 100 USD of revenue, 9.7 USD is left as net profit.
What to watch
- The share price is above the Bulios Fair Price.
- For every 100 USD of shareholders' equity it carries 3,329 USD of debt.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 36.1 USD for 1 USD of yearly profit. Over the last five years it was 31.0 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 4.4% a year over 5 years. Over the last 3 years it grew by 4.3% a year. For the next fiscal year analysts expect revenue to grow by 5.1%. Earnings per share grew by 7.3% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 40 USD
- Sales and administration 40 USD
- Taxes and other 11 USD
- Net profit 9.7 USD
Net profit, industry median (Household & Personal Products) 9.2 USD
Out of every 100 USD of revenue, 9.7 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 2.29%
- Paid out of profit
- 83%
- Raised in a row
- 11 years
You receive $2.11 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Neutral- Buy 18
- Hold 25
- Sell 2
Today's price within the analysts' price targets
The average target of $98.11 is 7.1% above today's price. 40% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Oral, Personal and Home Care 77%
- Pet Nutrition 23%
By region
- Oral, Personal and Home Care 61%
- Pet Nutrition 39%
Oral, Personal and Home Care brings in 77% of revenue. Pet Nutrition grew fastest, by 8.6% a year.
Segments in detail